EDSA Valuation

Edesa Biotech Inc

Add to Watchlist

Advanced Chart

2.400

+0.02(0.840%)1D

Overview
Forecast
Valuation
Earnings

EDSA Relative Valuation

EDSA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, EDSA is overvalued; if below, it's undervalued.

Historical Valuation

Edesa Biotech Inc (EDSA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.99. The fair price of Edesa Biotech Inc (EDSA) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：2.38

Fair

-1.74

Trailing

Forward

0.00

EV/EBITDA

Edesa Biotech Inc. (EDSA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.44. The thresholds are as follows: Strongly Undervalued below -3.45, Undervalued between -3.45 and -1.95, Fairly Valued between 1.06 and -1.95, Overvalued between 1.06 and 2.57, and Strongly Overvalued above 2.57. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-1.11

EV/EBIT

Edesa Biotech Inc. (EDSA) has a current EV/EBIT of -1.11. The 5-year average EV/EBIT is -1.13. The thresholds are as follows: Strongly Undervalued below -6.07, Undervalued between -6.07 and -3.60, Fairly Valued between 1.34 and -3.60, Overvalued between 1.34 and 3.81, and Strongly Overvalued above 3.81. The current Forward EV/EBIT of -1.11 falls within the Historic Trend Line -Fairly Valued range.

0.00

Edesa Biotech Inc. (EDSA) has a current PS of 0.00. The 5-year average PS is 9.88. The thresholds are as follows: Strongly Undervalued below -81.50, Undervalued between -81.50 and -35.81, Fairly Valued between 55.57 and -35.81, Overvalued between 55.57 and 101.26, and Strongly Overvalued above 101.26. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-1.14

P/OCF

Edesa Biotech Inc. (EDSA) has a current P/OCF of -1.14. The 5-year average P/OCF is -0.29. The thresholds are as follows: Strongly Undervalued below -4.74, Undervalued between -4.74 and -2.52, Fairly Valued between 1.93 and -2.52, Overvalued between 1.93 and 4.16, and Strongly Overvalued above 4.16. The current Forward P/OCF of -1.14 falls within the Historic Trend Line -Fairly Valued range.

-0.80

P/FCF

Edesa Biotech Inc. (EDSA) has a current P/FCF of -0.80. The 5-year average P/FCF is -0.17. The thresholds are as follows: Strongly Undervalued below -5.14, Undervalued between -5.14 and -2.66, Fairly Valued between 2.31 and -2.66, Overvalued between 2.31 and 4.80, and Strongly Overvalued above 4.80. The current Forward P/FCF of -0.80 falls within the Historic Trend Line -Fairly Valued range.

Edesa Biotech Inc (EDSA) has a current Price-to-Book (P/B) ratio of 3.37. Compared to its 3-year average P/B ratio of 3.02 , the current P/B ratio is approximately 11.51% higher. Relative to its 5-year average P/B ratio of 4.10, the current P/B ratio is about -17.80% higher. Edesa Biotech Inc (EDSA) has a Forward Free Cash Flow (FCF) yield of approximately -40.23%. Compared to its 3-year average FCF yield of -50.50%, the current FCF yield is approximately -20.33% lower. Relative to its 5-year average FCF yield of -37.19% , the current FCF yield is about 8.17% lower.

3.40

P/B

Median3y

3.02

Median5y

4.10

-39.62

FCF Yield

Median3y

-50.50

Median5y

-37.19

Competitors Valuation Multiple

The average P/S ratio for EDSA's competitors is 13.12, providing a benchmark for relative valuation. Edesa Biotech Inc Corp (EDSA) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Minerva Neurosciences Inc

Loss

17.03M

LEXX.O

Lexaria Bioscience Corp

Windtree Therapeutics Inc

Loss

1.95M

HOTH.O

Hoth Therapeutics Inc

Loss

17.24M

Performance Decomposition

Market capitalization of EDSA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of EDSA in the past 1 year is driven by Unknown.